MKI67 and central nervous system cancer: As shown in Table 1, the median Ki-67 expression was discernably higher in the glioma cohorts (median: 10.0%, range: 1.0–80.0%) than in the meningioma cohorts (median: 5.5%, range: 1.0–30.0%; p = 0.018).